R
R. Cuddihy
Researcher at World Health Organization
Publications - 9
Citations - 2219
R. Cuddihy is an academic researcher from World Health Organization. The author has contributed to research in topics: Randomized controlled trial & Sitagliptin. The author has an hindex of 8, co-authored 9 publications receiving 2027 citations. Previous affiliations of R. Cuddihy include University of Minnesota.
Papers
More filters
Journal ArticleDOI
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Faramarz Ismail-Beigi,Timothy E. Craven,Mary Ann Banerji,Jan Basile,Jorge Calles,Robert M. Cohen,R. Cuddihy,William C. Cushman,Saul Genuth,Richard H. Grimm,Bruce P. Hamilton,Byron J. Hoogwerf,Diane M. Karl,Lois A. Katz,Armand Krikorian,Patrick J. O'Connor,Rodica Pop-Busui,Ulrich K. Schubart,Debra L. Simmons,Harris C. Taylor,Abraham Thomas,Daniel J. Weiss,Irene Hramiak +22 more
TL;DR: Intensive therapy did not reduce the risk of advanced measures of microvascular outcomes, but delayed the onset of albuminuria and some measures of eye complications and neuropathy.
Journal ArticleDOI
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley,Michael A. Nauck,Timothy Bailey,Eduard Montanya,R. Cuddihy,Sebastiano Filetti,Anne B. Thomsen,Rie Elvang Søndergaard,Melanie J. Davies +8 more
TL;DR: Liraglutide was superior to sitagliptin for reduction of HbA(1c), and was well tolerated with minimum risk of hypoglycaemia, supporting the use of liragLutide as an effective GLP-1 agent to add to metformin.
Journal ArticleDOI
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel‐group, open‐label trial
Richard E. Pratley,Michael A. Nauck,Timothy L. Bailey,Eduard Montanya,R. Cuddihy,Sebastiano Filetti,Alan M. Garber,Anne B. Thomsen,H. Hartvig,Melanie J. Davies +9 more
TL;DR: The aim of this study was to compare the efficacy and safety of once‐daily human glucagon‐like peptide‐1 analogue liraglutide with dipeptidyl peptidase‐4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type 2 diabetes.
Journal ArticleDOI
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin
TL;DR: In this paper, a patient reported outcomes substudy aimed to evaluate treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at baseline and 26-weeks.
Short Report: Treatment Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin
TL;DR: In this paper, a patient reported outcomes substudy aimed to evaluate treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at baseline and 26 weeks was presented.